← Back to Search

Monoclonal Antibodies

Mavrilimumab for COVID-19

Phase 2
Waitlist Available
Led By Kristin Hudock, MD
Research Sponsored by Kristin Hudock
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This study is evaluating whether a drug may help prevent progression of respiratory failure in individuals with severe pneumonia.

Eligible Conditions
  • COVID-19
  • Pneumonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure
Secondary outcome measures
Measures

Side effects data

From 2021 Phase 2 trial • 40 Patients • NCT04399980
21%
Acute Respiratory Syndrome
16%
Acute Kidney Injury
16%
Hypoxia - Worsening
11%
Acute Respiratory Distress Syndrome
11%
Arrhythmia
11%
Pneumonia
11%
anemia
5%
Elevated Ferritin
5%
Elevated CRP
5%
Pulmonary Embolism
5%
Chronic Respiratory Failure
5%
Fever
5%
Elevated WBC
5%
Clot
5%
Delirium
5%
Hypotension
5%
Headache
5%
Worsening D Dimer
5%
Shock
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control
Intervention

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MavrilimumabExperimental Treatment1 Intervention
Mavrilimumab treatment infusion
Group II: PlaceboPlacebo Group1 Intervention
Placebo infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mavrilimumab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Kristin HudockLead Sponsor
Kiniksa Pharmaceuticals, Ltd.Industry Sponsor
8 Previous Clinical Trials
1,372 Total Patients Enrolled
3 Trials studying COVID-19
857 Patients Enrolled for COVID-19
Kristin Hudock, MDPrincipal Investigator - University of Cincinnati
University of Cincinnati Medical Center
Georgetown University School Of Medicine (Medical School)
Georgetown University Medical Center (Residency)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
Kristin Hudock 2020. "Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04492514.
All > Covid
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top